Explore how Croom Medical and GAM are revolutionizing 3D printed tantalum implants with advanced supply chain solutions and ...

Investors might want to bet on Penumbra (PEN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Lungpacer Medical today announced positive results from a Phase 1 clinical study evaluating its neurostimulation technology ...

Penumbra (NYSE:PEN – Free Report) had its price objective increased by Robert W. Baird from $305.00 to $328.00 in a report ...

Penumbra, Inc. (NYSE:PEN – Get Free Report)’s stock price hit a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $304.

Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Q4 2024 Earnings Call Transcript February 18, 2025 Penumbra, Inc. beats earnings expectations. Reported EPS is $0.97, ...

Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ETCompany ParticipantsCecilia Furlong - Director of ...

Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up ...